Sequoia China leads seed round for next-gen T cell therapy play

RootPath Inc. (Cambridge, Mass.) raised $7 million in a seed round led by Sequoia China. Fellow new investors Volcanics Venture, Baidu Ventures and Nest.Bio Ventures also participated.

Co-founder and CEO Xi Chen told BioCentury the funding provides a cash runway of 12-18 months...